In another study by Rossignol et al., a 72 h intravenous infusion and higher doses (500, 2,000 or 3,500 μg/h) of E5564 were administered into healthy volunteers (67) . E5564 has a slow plasma clearance (0.679 to 0.930 ml h −1 kg −1 of body weight), a small volume of distribution (45.6 to 49.8 ml/kg), and a relatively long half-life (50.4 to 62.7 h). All these pharmacokinetic parameters obtained are comparable to the study done by Wong et al. (74) . The association of E5564 with plasma lipoproteins was also investigated and it was found that the majority (∼55%) of the drug was bound specifically to high-density lipoprotein (HDL), but not low-density lipoproteins, very-low-density lipoproteins, or albumin (67) .